Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Arrowhead Pharmaceuticals  / Equity Bottom-Up

<ul><li>On May 7, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the second quarter of fiscal year 2026 that ended March 31, 2026 and provided a business update.</li><li>The launch of REDEMPLO (plozasiran) continues to show strength with total prescriptions to date since launch over 400, which includes >40% growth over just the past four weeks.</li><li>The company also secured positive regulatory action in four additional regions.</li></ul>

On May 7, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the second quarter of fiscal year 2026 that ended March 31, 2026 and provided a business update.The launch of REDEMPLO (plozasiran) continues to show strength with total prescriptions to date since launch over 400, which includes >40% growth over just the past four weeks.The company also secured positive regulatory action in four additional regions.

ARWR: Multiple Important Clinical Readouts in 2H26